Abstract: Provided are methods for clinical treatment of complement-associated conditions comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered (or is for administration) subcutaneously according to a particular clinical dosage regimen (i.e., at a particular dose amount and according to a specific dosing schedule). In one embodiment, the patient has previously been treated with eculizumab (SOLIRIS®) or ravulizumab (ULTOMIRIS®); particularly intravenously administered SOLIRIS® or ULTOMIRIS®.
Type:
Application
Filed:
May 6, 2021
Publication date:
September 28, 2023
Applicant:
Alexion Pharmaceuticals, Inc.
Inventors:
Dino C. Miano, Hweirung Amy Wang, Tatyana Mezhebovsky
Abstract: Provided herein are methods for treating cancer in a patient who has been determined to have positive expression of CD200 receptor (CD200R1) and one or more biomarkers (i.e., ICOS, TIGIT, TNFRSF9, HAVCR2, PDCD1, FCGR2A, FCGR1A, CD163, and/or CD14) by administering to the patient a CD200 inhibitor. Also provided are methods for monitoring responsiveness of a patient having cancer to treatment with a CD200 inhibitor, the method comprising: determining expression levels of CD200R1 and one or more biomarkers (i.e., ICOS, TIGIT, TNFRSF9, HAVCR2, PDCD1, FCGR2A, FCGR1A, CD163, and/or CD14) in a biological sample from the patient, wherein increased expression levels of CD200R1 and the one or more biomarkers, as compared to expression levels in a biological sample of the same type obtained from the subject prior to treatment with the CD200 inhibitor, indicates that the subject is responsive to treatment with the CD200 inhibitor.
Abstract: Novel crystalline particles, methods for manufacture of crystalline particles, and solid unit dosage forms, particularly tablets or capsules, of bis-choline tetrathiomolybdate are provided. In particular, provided herein are crystalline particles that allow for a more stable solid unit dosage form of bis-choline tetrathiomolybdate.
Abstract: The present disclosure relates kits and methods for measuring the potency of an andexanet sample in neutralizing a factor Xa inhibitor and restoring the activity of a wild-type factor Xa.
Type:
Application
Filed:
June 10, 2021
Publication date:
August 24, 2023
Applicant:
Alexion Pharmaceuticals, Inc.
Inventors:
Joel Freeberg, Genmin Lu, Pamela Conley
Abstract: Forms of cerdulatinib and salts or co-crystals thereof were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the forms cerdulatinib and salts or co-crystals thereof.
Type:
Grant
Filed:
November 16, 2020
Date of Patent:
August 1, 2023
Assignee:
Alexion Pharmaceuticals, Inc.
Inventors:
Anjali Pandey, Julian Scott Northen, Philippe Fernandes, Ying Chen, Yuelie Lu, Sami Karaborni, Gus Kodersha
Abstract: Provided are methods for clinical treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in pediatric patients using an anti-C5 antibody, or antigen binding fragment thereof.
Type:
Application
Filed:
July 8, 2021
Publication date:
July 27, 2023
Applicant:
Alexion Pharmaceuticals, Inc.
Inventors:
Lori Payton, Scott T. Rottinghaus, Rajendra Pradhan, Stephan Ortiz, Masayo Ogawa, Xiang Gao
Abstract: Methods for treating B cell lymphomas are provided. B cell lymphomas patients suitable for treatments can be identified based on the baseline B cell subset frequencies. For instance, increased frequency of transitional (CD10+) B cells within total nave B cells or within total B cells predicts poor response to kinase inhibitors. By contrast, having an increased nave B cells to total B cells frequency without an increased transitional (CD10+) B cell frequency predicts good response to the kinase inhibitors. Having a decreased frequency of nave B cells of the total B cell population with a corresponding increase in frequency of memory switched and double negative B cells of the total B cell population also predicts good response to the kinase inhibitors. Once the patients are identified, the patients can be suitably treated with the kinase inhibitors such as cerdulatinib.
Type:
Application
Filed:
May 20, 2021
Publication date:
June 15, 2023
Applicant:
Alexion Pharmaceuticals, Inc.
Inventors:
Gregory Coffey, Matthew Birrell, Pamela B. Conley, Andreas H. Betz
Abstract: Provided are methods for treating paroxysmal nocturnal hemoglobinuria in a subject who previously exhibited an inadequate response to an anti-C5 antibody therapy, by administering to the subject a therapeutically effective amount of an inhibitor of the alternative pathway of complement (e.g., one which inhibits a target upstream to complement 5 (C5), such as Factor D or complement 3 (C3)). Also provided herein are methods for treating PNH in a human subject, comprising administering to the subject a complement factor D inhibitor alone or in combination with an anti-C5 antibody, or antigen binding fragment thereof. In some embodiments, the patient previously exhibited an inadequate response to an anti-C5 antibody therapy.
Type:
Application
Filed:
May 11, 2021
Publication date:
June 8, 2023
Applicant:
Alexion Pharmaceuticals, Inc.
Inventors:
Mingjun Huang, James Hui, Steven Podos, Dharaben Patel, Michael Geffner
Abstract: Forms of cerdulatinib and salts or co-crystals thereof were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the forms cerdulatinib and salts or co-crystals thereof.
Type:
Grant
Filed:
November 16, 2020
Date of Patent:
May 30, 2023
Assignee:
Alexion Pharmaceuticals, Inc.
Inventors:
Anjali Pandey, Julian Scott Northen, Philippe Fernandes, Ying Chen, Yuelie Lu, Sami Karaborni, Gus Kodersha
Abstract: This disclosure relates to inexpensive and efficient methods of preparing egg white (e.g., obtained from eggs laid by transgenic chickens) for bulk chromatographic isolation of proteins (e.g., recombinant proteins) from the egg white, as well as method of filtering acidified egg white and methods of isolating proteins from the egg white.
Type:
Application
Filed:
November 11, 2022
Publication date:
May 25, 2023
Applicant:
ALEXION PHARMACEUTICALS, INC.
Inventors:
Liang CHEN, Markley C. LEAVITT, Michael TITUS
Abstract: Disclosed are methods for purifying antibodies using a Protein A Chromatography Column and an arginine wash, resulting in decreased host cell protein (HCP) contamination. The method may comprise loading a composition comprising an antibody on a Protein A Chromatography column and washing the column with a wash solution. In an embodiment, the wash is repeated.
Abstract: The disclosure provides antibody immune cell inhibitor fusion proteins comprising four polypeptide chains that form two antigen binding sites and at least two immune cell receptor binding sites that inhibit or diminish activation of an immune effector cell when bound to a target antigen. The disclosure also provides antibody immune cell inhibitor fusion proteins comprising two polypeptide chains that form one antigen binding site and at least one immune cell receptor binding site that inhibit or diminish activation of an immune effector cell when bound to a target antigen. The disclosure further provides pharmaceutical compositions and kits that comprise such antibody immune cell inhibitor fusion proteins, and methods of treatment using such proteins.
Abstract: Provided are methods for clinical treatment of pregnancy-associated atypical haemolytic uraemic syndrome (p-aHUS), including postpartum aHUS, using an anti-C5 antibody, or antigen binding fragment thereof, such as ravulizumab (ULTOMIRIS®).
Abstract: Provided are methods for clinical treatment of neuromyelitis optica spectrum disorder (NMOSD) using an anti-C5 antibody, or antigen binding fragment thereof.
Type:
Application
Filed:
December 8, 2020
Publication date:
February 9, 2023
Applicant:
Alexion Pharmaceuticals, Inc.
Inventors:
Kerstin Allen, Marcus Yountz, Stephan Ortiz, Fanny O'Brien
Abstract: Disclosed herein are methods for treating a subject with an alkaline phosphatase deficiency, further comprising monitoring additional analytes, e.g., calcium, parathyroid hormone and/or vitamin D, with treatment modifications as indicated by the levels, e.g., serum levels, of the additional analytes.
Abstract: The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.
Abstract: The present disclosure relates to stable aqueous solutions comprising a high concentration of an anti-C5 antibody (e.g., ravulizumab) and methods for preparing the solutions. The disclosure also provides methods for treating or preventing complement-associated disorders, such as paroxysmal nocturnal hemoglobinuria (PNH) and thrombotic microangiopathy (TMA), including atypical hemolytic uremic syndrome (aHUS) using the solutions. Also featured are therapeutic kits containing one or more of the solutions.
Abstract: This disclosure generally relates to methods of treating copper-induced neurological damage observed in copper metabolism-associated diseases or disorders. This disclosure relates to reducing the copper-induced neurological damage in Wilson disease (WD).
Type:
Application
Filed:
November 20, 2020
Publication date:
December 8, 2022
Applicant:
Alexion Pharmaceuticals, Inc.
Inventors:
Thomas Plitz, Sabine Borchard, Hans Zischka
Abstract: Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided. The methods may include administering 15 mg or between 30 and 90 mg of bis-choline tetrathiomolybdate once daily to a patient exhibiting NCC corrected, alamine aminotransferase (ALT), hemoglobin, platelets, or neutrophils levels meeting specified criteria. The methods may include modifying treatment by decreasing or increasing the daily dose of bis-choline tetrathiomolybdate or discontinuing treatment for a period of time.
Type:
Grant
Filed:
December 4, 2018
Date of Patent:
November 29, 2022
Assignee:
Alexion Pharmaceuticals, Inc.
Inventors:
Carl Bjartmar, Karl-Heinz Weiss, Michael Schilsky, Frederick Askari, Anna Czlonkowska, Peter Ferenci, Peter Hedera, Aftab Ala
Abstract: The disclosure provides engineered polypeptides that specifically bind to human complement component C5 and/or serum albumin. The disclosure also provides fusion proteins comprising such engineered polypeptides, wherein such fusion proteins may be multivalent and multi-specific fusion proteins. The disclosure further provides nucleic acid molecules that encode such engineered polypeptides or fusion proteins, and methods of making such engineered polypeptides or fusion proteins. The disclosure further provides pharmaceutical compositions that comprise such engineered polypeptides or fusion proteins, and methods of treatment using such engineered polypeptides or fusion proteins.
Type:
Grant
Filed:
July 11, 2018
Date of Patent:
November 15, 2022
Assignee:
Alexion Pharmaceuticals, Inc.
Inventors:
Bridget Puffer, Julian Chandler, Nimish Gera, Douglas L. Sheridan, Siddharth Jindal, Paul P. Tamburini